<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The L-type amino acid transporter-1 (LAT-1) has been associated with <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Using cDNA microarrays, overexpression of LAT-1 was found in 87.5% (7/8) of esophageal <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> relative to 12 Barrett's samples (33% <z:mpath ids='MPATH_160'>metaplasia</z:mpath> and 66% <z:mpath ids='MPATH_589'>dysplasia</z:mpath>) and was confirmed in 100% (28/28) of Barrett's <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> by quantitative reverse transcription polymerase chain reaction </plain></SENT>
<SENT sid="2" pm="."><plain>Immunohistochemistry revealed LAT-1 staining in 37.5% (24/64) of esophageal <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> on tissue microarray </plain></SENT>
<SENT sid="3" pm="."><plain>LAT-1 also transports the amino acid-related chemotherapeutic agent, melphalan </plain></SENT>
<SENT sid="4" pm="."><plain>Two esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> and one esophageal squamous cell line, expressing LAT-1 on Western blot analysis, were sensitive to therapeutic doses of melphalan (P &lt;.001) </plain></SENT>
<SENT sid="5" pm="."><plain>Simultaneous treatment with the competitive inhibitor, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BCH</z:e> [2-aminobicyclo-(2,1,1)-<z:chebi fb="1" ids="43098">heptane</z:chebi>-2-<z:chebi fb="1" ids="33575">carboxylic acid</z:chebi>], decreased sensitivity to melphalan (P &lt;.05) </plain></SENT>
<SENT sid="6" pm="."><plain>In addition, confluent esophageal squamous cultures were less sensitive to melphalan (P &lt;.001) and had a decrease in LAT-1 protein expression </plain></SENT>
<SENT sid="7" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumors</z:e> from two esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> cell lines grown in <z:mp ids='MP_0003815'>nude</z:mp> mice retained LAT-1 mRNA expression </plain></SENT>
<SENT sid="8" pm="."><plain>These results demonstrate that LAT-1 is highly expressed in a subset of esophageal <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> and that Barrett's <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> cell lines expressing LAT-1 are sensitive to melphalan </plain></SENT>
<SENT sid="9" pm="."><plain>LAT-1 expression is also retained in cell lines grown in <z:mp ids='MP_0003815'>nude</z:mp> mice providing a model to evaluate melphalan as a chemotherapeutic agent against esophageal <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> expressing LAT-1 </plain></SENT>
</text></document>